comparemela.com

Latest Breaking News On - Epicentrx cy - Page 1 : comparemela.com

EpicentRx Awarded Funding from FightMND to Evaluate Therapeutic Potential of RRx-001 in Motor Neuron Disease (aka ALS)

/PRNewswire/ EpicentRx Inc. ("EpicentRx"), a late-stage biopharmaceutical company with platforms that treat and target multiple immune-mediated inflammatory.

San diegoUnited statesRob hendersonEpicentrx cyRichard gordonTonyr reidPam mccombeTranslational research instituteQueensland university of technologyPrnewswire epicentrx incCentre for microbiome researchMichaelj fox foundation for parkinson researchAssociate professor richard gordonQueensland universityMicrobiome researchCentral nervous system

EpicentRx Announces Presentations Focusing on RRx-001 Inhibition of the NLRP3 Inflammasome at Two Upcoming Scientific Conferences

/PRNewswire/ EpicentRx, a late clinical stage biopharmaceutical company with novel therapies to target cancer and inflammatory diseases, announced it will.

United statesSan diegoPrnewswire epicentrxEpicentrx cyInflammasome therapeutics summitControl numberDisease molecularProtects against inflammasome drivenProof of concept trialsVarious disease groupsClinical relevance

EpicentRx Awarded Grant from The Michael J Fox Foundation to Evaluate Therapeutic Potential of RRx-001 in Parkinson s Disease

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Shalini padmanabhanRichard gordonEpicentrx cyTonyr reidAustralia foundationUniversity of queenslandPrnewswire epicentrx incResearch programsMichaelj fox foundationEpicentrx incMichaelj fox foundation for parkinson researchCentral nervous systemChief executive officerPr newswireParkinson x27s diseaseMichaelj fox

Actinium Pharmaceuticals, Inc and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.

Astellas pharmaEpicentrx cyEpicentrx rrxTonyr reidSandesh sethHans vitzthumLifesci advisorsTaft communicationsSociety for immunotherapy of cancerExchange commissionAstellas pharma incActinium pharmaceuticals incEpicentrx incMemorial sloan kettering cancer centerPrnewswire actinium pharmaceuticals incSan diego based

Actinium Pharmaceuticals, Inc and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.

Astellas pharmaEpicentrx cyEpicentrx rrxTonyr reidSandesh sethHans vitzthumLifesci advisorsTaft communicationsSociety for immunotherapy of cancerExchange commissionAstellas pharma incActinium pharmaceuticals incEpicentrx incMemorial sloan kettering cancer centerPrnewswire actinium pharmaceuticals incSan diego based

vimarsana © 2020. All Rights Reserved.